Erasca to Present at the Bank of America Securities 2022 Healthcare Conference
May 03, 2022 08:00 ET
|
Erasca, Inc.
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Appoints Jean Liu to its Board of Directors
April 27, 2022 08:00 ET
|
Erasca, Inc.
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting
April 12, 2022 16:01 ET
|
Erasca, Inc.
ERAS-007 is a potent and selective small molecule ERK1/2 inhibitor with long target residence time, which promotes sustained RAS/MAPK pathway inhibition ERAS-601 is a potent and selective small...
Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway
April 06, 2022 08:00 ET
|
Erasca, Inc.
Virtual event on Tuesday, April 12 at 4:30 PM ET will feature key opinion leader (KOL) Scott Kopetz, M.D., Ph.D., from MD Anderson Cancer Center Company and KOL to discuss an overview of unmet...
Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates
March 24, 2022 16:05 ET
|
Erasca, Inc.
Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi) Initial Phase 1b data for HERKULES-1 and Phase 1 data for FLAGSHP-1 expected...
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination
March 10, 2022 08:00 ET
|
Erasca, Inc.
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated clinically in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant mCRC Erasca previously signed a...
Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting
March 08, 2022 16:31 ET
|
Erasca, Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day
February 03, 2022 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Strengthens Leadership Team with Two Key Executive Appointments
January 18, 2022 08:00 ET
|
Erasca, Inc.
Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a...
Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 08:00 ET
|
Erasca, Inc.
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...